Supplementary Figure 8

(A) Objective response rate, (B) progression-free, and (C) overall survival to pembrolizumab monotherapy by ctDNA decrease versus increase. (D) Objective response rate, (E) progression-free, and (F) overall survival to pembrolizumab + chemotherapy by ctDNA decrease versus increase.